左西孟旦对脓毒症患者膈肌功能障碍的影响
这项单盲随机对照试验纳入44例脓毒症合并膈肌功能障碍且自主呼吸试验失败的患者,随机等分为左西孟旦组和对照组。左西孟旦组给予负荷剂量6 μg/kg持续10 min,随后以0.2 μg/kg/min持续输注;对照组给予等量安慰剂。给药后左西孟旦组潮气量增加、D-RSBI降低、二氧化碳分压降低,膈肌位移(1.14±0.177 vs 1.22±0.170 cm)和压力支持(0.248±0.03 vs 0.284±0.06)增加、D-RSBI(22.76±6.14 vs 20.06±6.04)降低,均P<0.05;对照组给药前后DE、TFdi、D-RSBI无统计学显著差异(P>0.05)。两组最终脱机人数无统计学显著差异(P=0.545)。作者结论为左西孟旦增强膈肌收缩功能,但脱机结局需进一步研究。
要点
- 左西孟旦组给药后膈肌位移由1.14±0.177 cm增至1.22±0.170 cm,D-RSBI由22.76±6.14降至20.06±6.04,均P<0.05。
- 左西孟旦组给药后压力支持由0.248±0.03增至0.284±0.06,潮气量增加、二氧化碳分压降低,均P<0.05。
- 对照组给药前后DE、TFdi、D-RSBI均无统计学显著差异(P>0.05)。
- 两组最终脱机人数无统计学显著差异(P=0.545)。
- 作者结论:左西孟旦增强膈肌收缩功能,但对脱机结局的影响需进一步研究。
适用人群与场景
- 脓毒症合并膈肌功能障碍且自主呼吸试验失败的患者。
处置流程与药物剂量
- 实验组:左西孟旦负荷剂量6 μg/kg持续10 min,随后以0.2 μg/kg/min持续输注。
- 对照组:给予等量安慰剂。
研究设计与关键结果
- 单盲随机对照试验,纳入44例脓毒症合并膈肌功能障碍且自主呼吸试验失败的患者,随机等分为实验组和对照组。
- 左西孟旦组给药后与给药前比较:膈肌位移1.14±0.177 vs 1.22±0.170 cm、压力支持0.248±0.03 vs 0.284±0.06、D-RSBI 22.76±6.14 vs 20.06±6.04,均P<0.05;潮气量增加、二氧化碳分压降低。
- 对照组给药后与给药前比较:DE、TFdi、D-RSBI均无统计学显著差异(P>0.05)。
- 脱机结局:两组最终脱机人数无统计学显著差异(P=0.545)。
证据类型、等级与局限
- 证据类型:单盲随机对照试验。
- 局限:作者指出需进一步研究以探索左西孟旦对机械通气患者脱机结局的影响。
对床旁实践的改变
- 在脓毒症合并膈肌功能障碍且自主呼吸试验失败的患者中,左西孟旦可增强膈肌收缩功能(给药后DE、压力支持增加,D-RSBI降低,均P<0.05)。
- 作者结论:左西孟旦对脱机结局的影响需进一步研究,本研究中两组脱机人数无统计学显著差异(P=0.545)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Objective: In this study, our aim was to examine the effects of levosimendan on diaphragmatic dysfunction in patients with sepsis, as well as assess its impact on respiratory muscle contractility and the outcome of weaning. Methods: This was a single-blind, randomized, controlled trial. Patients with diaphragmatic dysfunction and failure of spontaneous breathing trials (SBTs) were randomly and equally assigned to the experimental and control groups. The experimental group received levosimendan at a loading dose of 6 μg/kg for 10 min, followed by a continuous infusion at 0.2 μg/kg/min. The control group received an equivalent dose of a placebo. The preadministration and postadministration respiratory mechanics parameters of the patients were recorded. Evaluation of the effect of levosimendan on patients with sepsis-induced diaphragm dysfunction comprised arterial blood gas analysis as well as ultrasound measurements of diaphragm excursion (DE), diaphragm thickness (DT), diaphragm thickening fraction (TFdi), and diaphragm-rapid shallow breathing index (D-RSBI). Results: Forty-four patients were enrolled in the study. We found that postadministration of levosimendan, the patients' tidal volume (GCSMV) increased, whereas the D-RSBI decreased, and the partial pressure of carbon dioxide (PACO 2 ) decreased when compared to the preadministration levels. Additionally, following levosimendan administration, patients showed increased DE and pressure support (PS) when compared to before administration (1.14 ± 0.177 vs. 1.22 ± 0.170 cm and 0.248 ± 0.03 vs. 0.284 ± 0.06, respectively) and decreased D-RSBI (22.76 ± 6.14 vs. 20.06 ± 6.04, respectively), all of which were statistically significant ( P < 0.05). In contrast, in the control group of patients, there were no statistically significant differences in the postadministration levels of DE, TFdi, and D-RSBI as compared to the preadministration period ( P > 0.05). Furthermore, in terms of weaning outcomes, we did not find any statistically significant difference in the number of patients in the two groups who eventually underwent weaning ( P = 0.545). Conclusion: In this study, we found that levosimendan enhanced diaphragm contractile function. However, further investigations are required to explore its effect on weaning outcomes in patients undergoing mechanical ventilation.
参考来源
- Wu JQ, Wang YX, Su D, et al. EFFECTS OF LEVOSIMENDAN ON DIAPHRAGMATIC DYSFUNCTION IN PATIENTS WITH SEPSIS. Shock. 2024. PMID: 38661179. doi:10.1097/SHK.0000000000002372
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。